Sun Pharma

Sun Pharma Launches Website for its Long-Term Care Portfolio in the U.S.

Thursday, February 25, 2021 - 10:00am

The Ezallor Sprinkle label was recently updated to allow for sprinkling the capsule contents over pudding (in addition to applesauce) as a soft-food alternative mode of administration.

Key Points: 
  • The Ezallor Sprinkle label was recently updated to allow for sprinkling the capsule contents over pudding (in addition to applesauce) as a soft-food alternative mode of administration.
  • Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.
  • Its global presence is supported by manufacturing facilities spread across 6 continents and approved by multiple regulatory agencies, coupled with a multi-cultural workforce comprising over 50 nationalities.
  • Sun Pharma fosters excellence through innovation supported by strong R&D capabilities across multiple R&D centers, with investments of approximately 6% of annual revenues in R&D.

Innocan Pharma Announces the Completion of its First Full-Scale Manufacturing Run in the US and the Launching of its US Commercial Online Platform

Monday, February 22, 2021 - 9:00pm

Innocan has successfully completed its first commercial manufacturing run in the US of 40,000 Units of its SYNONY and Relief & Go brands.

Key Points: 
  • Innocan has successfully completed its first commercial manufacturing run in the US of 40,000 Units of its SYNONY and Relief & Go brands.
  • In addition, Innocan is pleased to announce the launch of its North American commercial web-platform www.synonyshop.com .
  • The Company, through its wholly owned subsidiary Innocan Pharma Ltd ("Innocan Israel"), has set in place agreements with world-leading companies for the fulfillment, logistics, and service required to support the activities on this website.
  • The founders and officers of Innocan have commercially successful track records in the pharmaceutical and technology sectors in Israel and globally.

Pharma Two B Appoints Sheila Oren, M.D., M.B.A., as Chief Executive Officer

Tuesday, January 5, 2021 - 12:00pm

REHOVOT, Israel, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Pharma Two B Ltd., a privately held company developing innovative therapeutics based on previously approved drugs for Parkinson disease, today announced that Sheila Oren, M.D., M.B.A., was appointed Chief Executive Officer of Pharma Two B, effective January 1, 2021.

Key Points: 
  • REHOVOT, Israel, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Pharma Two B Ltd., a privately held company developing innovative therapeutics based on previously approved drugs for Parkinson disease, today announced that Sheila Oren, M.D., M.B.A., was appointed Chief Executive Officer of Pharma Two B, effective January 1, 2021.
  • In tandem, I look forward to exploring new opportunities to expand Pharma Two Bs pipelinedelivering on the Companys mission to develop innovative therapeutics for patients.
  • Pharma Two B is a clinical-stage pharmaceutical company that is developing differentiated and value-added products, based on previously approved drugs.
  • Pharma Two B is led by highly experienced team, supported by prominent scientific and clinical key opinion leaders, and backed by a dedicated group of investors.

New Dermatology Company Resilia Pharmaceuticals Begins Operations

Monday, December 28, 2020 - 11:30am

"These four branded dermatology products represent a strong platform from which to build a new pharma company dedicated to promoting outstanding patient outcomes," said Harsha Murthy, Executive Chairman of the Board of Directors of Resilia Pharmaceuticals.

Key Points: 
  • "These four branded dermatology products represent a strong platform from which to build a new pharma company dedicated to promoting outstanding patient outcomes," said Harsha Murthy, Executive Chairman of the Board of Directors of Resilia Pharmaceuticals.
  • "We at Resilia bring our industry experience to the important business of promoting health.
  • Resilia Pharmaceuticals, Inc. is a portfolio company of Peak Pharma Commercial Partners, a New York City-based investment fund dedicated to the acquisition and growth of branded, generic and over-the-counter pharmaceutical products ( www.peakpharmapartners.com ).Resilia is based in Atlanta, Georgia.
  • In addition to Harsha Murthy, Resilia Pharmaceuticals' senior management team consists of pharmaceutical industry veterans Andrew Shales, President & CEO, and Mike Leone, Chief Operating Officer.

Chipscreen and HISUN reach a strategic cooperation

Wednesday, December 16, 2020 - 10:06am

SHENZHEN, China, Dec. 16, 2020 /PRNewswire/ -- On December 16, 2020, SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (hereinafter referred to as: CHIPSCREEN BIOSCIENCES) and ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (hereinafter referred to as: HISUN PHARMACEUTICAL) announced that they have reached a strategic cooperation.

Key Points: 
  • SHENZHEN, China, Dec. 16, 2020 /PRNewswire/ -- On December 16, 2020, SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (hereinafter referred to as: CHIPSCREEN BIOSCIENCES) and ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (hereinafter referred to as: HISUN PHARMACEUTICAL) announced that they have reached a strategic cooperation.
  • Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen Biosciences, Stock Symbol: 688321.SH) was founded inShenzhenon 2001, specializing in the research and development of novel small molecule drugs.
  • HISUN PHARMACEUTICAL has developed into a "pharmaceutical industry group" composed of business including raw materials, preparations, biological drugs, innovative drugs, and commercial distribution.
  • HISUN PHARMACEUTICAL's R&D and drug development covers therapeutic fields including oncology, anti-infection, cardiovascular, endocrine, immunosuppression, anti-depression, and orthopedics.

Shareholder Alert: Robbins LLP Announces Zosano Pharma Corporation (ZSAN) is Being Sued for Misleading Shareholders

Monday, November 2, 2020 - 11:51pm

Shareholder rights law firm Robbins LLP announces that a purchaser of Zosano Pharma Corporation (NASDAQ: ZSAN) filed a class action complaint against the Company and its officers and directors for alleged violations of the Securities & Exchange Act of 1934 between February 13, 2017 and September 30, 2020.

Key Points: 
  • Shareholder rights law firm Robbins LLP announces that a purchaser of Zosano Pharma Corporation (NASDAQ: ZSAN) filed a class action complaint against the Company and its officers and directors for alleged violations of the Securities & Exchange Act of 1934 between February 13, 2017 and September 30, 2020.
  • Zosano Pharma is a clinical stage pharmaceutical company.
  • If you suffered a loss due to Zosano Pharma's misconduct, click here .
  • In December 2019, Zosano submitted its New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") seeking regulatory approval for Qtrypta.

Global Buprenorphine Market to Surpass US$ 10,898.8 Million by 2027, Says Coherent Market Insights (CMI)

Thursday, October 15, 2020 - 2:22pm

According to Coherent Market Insights, the global buprenorphine market is estimated to be valued at US$ 3,681.9 million in 2020 and is expected to exhibit a CAGR of 14.5% during the forecast period (2020-2027).

Key Points: 
  • According to Coherent Market Insights, the global buprenorphine market is estimated to be valued at US$ 3,681.9 million in 2020 and is expected to exhibit a CAGR of 14.5% during the forecast period (2020-2027).
  • Market players are actively launching generic versions of buprenorphine for cost effective and quality treatment.
  • Moreover, the players are committed to offer new and improved products to address the critical unmet needs of patients.
  • Key players operating in the global buprenorphine market are Siegfried, Sanofi, Johnson Matthey, Mallinckrodt, Noramco, Inc., Unichem Laboratories, Arevipharma GmbH, Resonance-labs, Sun Pharmaceutical Industries Ltd., Rusan Pharma, Micro Orgo Chem, and Faran Shimi Pharmaceutical Co.

Dr. Reddy's to Release Q2 FY 21 Results on October 28th, 2020

Monday, October 12, 2020 - 1:51pm

The operator will provide instructions on asking questions before and during the call.

Key Points: 
  • The operator will provide instructions on asking questions before and during the call.
  • About Dr. Reddys: Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.
  • Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products Dr. Reddys offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.
  • Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.

Raziel Announces China Market License Agreement with Fosun Pharma for RZL 012

Thursday, September 17, 2020 - 1:00pm

Today Mr. Alon Bloomenfeld announced that Raziel Therapeutics has entered into a license agreement with Tianjin JuveStar Biotech Co., Ltd., (JuveStar), a company invested and incubated by the venture capital arm of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma, stock code: 600196.SH, 02196.HK).

Key Points: 
  • Today Mr. Alon Bloomenfeld announced that Raziel Therapeutics has entered into a license agreement with Tianjin JuveStar Biotech Co., Ltd., (JuveStar), a company invested and incubated by the venture capital arm of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma, stock code: 600196.SH, 02196.HK).
  • "Fosun Pharma is one of the leading healthcare companies in China, with expertise and access to both the aesthetic and therapeutic markets.
  • We see Fosun Pharma as an ideal partner to commercialize RZL-012 in the fast-growing aesthetic Chinese market, said Alon Bloomenfeld, president and chief executive officer at Raziel Therapeutics.
  • Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"; stock code: 600196.SH, 02196.HK) is a leading healthcare group in China.

LEO Pharma Sells Portfolio of Four Products to Cheplapharm

Monday, August 31, 2020 - 11:30am

Today, LEO Pharma A/S announced the sale of a portfolio of four non-core products to Cheplapharm for EUR 300 million.

Key Points: 
  • Today, LEO Pharma A/S announced the sale of a portfolio of four non-core products to Cheplapharm for EUR 300 million.
  • The divested portfolio comprises four products within bone disorders/nephrology, dermatology and gynecology: One-Alpha, Locoid, Pimafucin, and Zineryt.
  • We are delighted to seize this unique opportunity to acquire a sizeable portfolio of mature and well-known branded pharmaceuticals from LEO Pharma.
  • Following the closing, LEO Pharma and Cheplapharm will work closely together to ensure a smooth and effective transition of the products and business.